EVO – Evotec SE
Evotec SEEVO
$1.69Name : Evotec SE
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $600,607,616.00
EPSttm : -0.59
Evotec SE
$1.69
0.00%$0.00000000000000
EVO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.02
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-1.15
EPS This/Next Y
1.55
Price
1.69
Target Price
2.47
Analyst Recom
2.33
Performance Q
-22.83
Upside
-1,321.9%
Beta
2
Ticker: EVO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | EVO | 1.37 | N/A | N/A | 0 |
| 2026-10-13 | EVO | 1.35 | N/A | N/A | 0 |
| 2026-10-14 | EVO | 1.425 | N/A | N/A | 0 |
| 2026-10-15 | EVO | 1.415 | N/A | N/A | 0 |
| 2026-10-16 | EVO | 1.39 | N/A | N/A | 0 |
| 2026-10-19 | EVO | 1.425 | N/A | N/A | 0 |
| 2026-10-20 | EVO | 1.485 | N/A | N/A | 0 |
| 2026-10-21 | EVO | 1.55 | N/A | N/A | 0 |
| 2026-10-22 | EVO | 1.535 | N/A | N/A | 0 |
| 2026-10-23 | EVO | 1.51 | N/A | N/A | 0 |
| 2026-10-26 | EVO | 1.52 | N/A | N/A | 0 |
| 2026-10-27 | EVO | 1.565 | N/A | N/A | 0 |
| 2026-10-28 | EVO | 1.605 | N/A | N/A | 0 |
| 2026-10-29 | EVO | 1.58 | N/A | N/A | 0 |
| 2026-10-30 | EVO | 1.53 | N/A | N/A | 0 |
| 2026-11-02 | EVO | 1.52 | N/A | N/A | 0 |
| 2026-11-03 | EVO | 1.54 | N/A | N/A | 0 |
| 2026-11-04 | EVO | 1.55 | N/A | N/A | 0 |
| 2026-11-05 | EVO | 1.74 | N/A | N/A | 0 |
| 2026-11-06 | EVO | 1.695 | N/A | N/A | 0 |
| 2026-11-09 | EVO | 1.73 | N/A | N/A | 0 |
| 2026-11-10 | EVO | 1.69 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | EVO | 1.37 | - | - | -1.44 |
| 2026-10-13 | EVO | 1.34 | - | - | -1.44 |
| 2026-10-14 | EVO | 1.43 | - | - | -1.44 |
| 2026-10-15 | EVO | 1.42 | - | - | -1.44 |
| 2026-10-16 | EVO | 1.39 | - | - | -1.48 |
| 2026-10-19 | EVO | 1.42 | - | - | -1.48 |
| 2026-10-20 | EVO | 1.42 | - | - | -1.48 |
| 2026-10-21 | EVO | 1.49 | - | - | -1.48 |
| 2026-10-22 | EVO | 1.54 | - | - | -1.48 |
| 2026-10-23 | EVO | 1.51 | - | - | -1.48 |
| 2026-10-26 | EVO | 1.52 | - | - | -1.48 |
| 2026-10-27 | EVO | 1.57 | - | - | -1.48 |
| 2026-10-28 | EVO | 1.61 | - | - | -1.48 |
| 2026-10-29 | EVO | 1.58 | - | - | -1.48 |
| 2026-10-30 | EVO | 1.54 | - | - | -1.48 |
| 2026-11-02 | EVO | 1.53 | - | - | -1.48 |
| 2026-11-03 | EVO | 1.55 | - | - | -1.48 |
| 2026-11-04 | EVO | 1.55 | - | - | -1.48 |
| 2026-11-05 | EVO | 1.79 | - | - | -1.48 |
| 2026-11-06 | EVO | 1.70 | - | - | -1.48 |
| 2026-11-09 | EVO | 1.74 | - | - | -1.48 |
| 2026-11-10 | EVO | 1.69 | - | - | -1.48 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | EVO | 0.00 | -0.05 | 0.01 |
| 2026-10-13 | EVO | 0.00 | -0.05 | 0.01 |
| 2026-10-14 | EVO | 0.00 | -0.05 | 0.01 |
| 2026-10-15 | EVO | 0.00 | -0.05 | 0.01 |
| 2026-10-16 | EVO | 0.00 | -0.05 | 0.01 |
| 2026-10-19 | EVO | 0.00 | -3.83 | 0.01 |
| 2026-10-20 | EVO | 0.00 | -3.83 | 0.01 |
| 2026-10-21 | EVO | 0.00 | -3.83 | 0.01 |
| 2026-10-22 | EVO | 0.00 | -3.83 | 0.01 |
| 2026-10-23 | EVO | 0.00 | -3.83 | 0.01 |
| 2026-10-26 | EVO | 0.00 | -3.73 | 0.01 |
| 2026-10-27 | EVO | 0.00 | -3.73 | 0.02 |
| 2026-10-28 | EVO | 0.00 | -3.73 | 0.02 |
| 2026-10-29 | EVO | 0.00 | -3.73 | 0.02 |
| 2026-10-30 | EVO | 0.00 | -3.73 | 0.02 |
| 2026-11-02 | EVO | 0.00 | -3.81 | 0.02 |
| 2026-11-03 | EVO | 0.00 | -3.81 | 0.02 |
| 2026-11-05 | EVO | 0.00 | -3.81 | 0.02 |
| 2026-11-06 | EVO | 0.00 | -3.81 | 0.02 |
| 2026-11-09 | EVO | 0.00 | -3.27 | 0.02 |
| 2026-11-10 | EVO | 0.00 | -3.27 | 0.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.32
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-3.27
Beta
2
Average Sales Estimate Current Quarter
139
Average Sales Estimate Next Quarter
215
Fair Value
Quality Score
36
Growth Score
32
Sentiment Score
75
Actual DrawDown %
93.3
Max Drawdown 5-Year %
-94.6
Target Price
2.47
P/E
Forward P/E
PEG
P/S
0.72
P/B
0.82
P/Free Cash Flow
EPS
-0.59
Average EPS Est. Cur. Y
-1.48
EPS Next Y. (Est.)
0.07
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-25.24
Relative Volume
0.81
Return on Equity vs Sector %
-54.5
Return on Equity vs Industry %
-34.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
◆
EVO
Healthcare
$1.69
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56.5
Range 1M
71.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-137.2%
EPS NY
73.5%
52W%
13.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+45.3% upside
Upside
+45.3%
Quality
36
EVO — P/E HistoricalDrug Manufacturers - Specialty & Generic
Evotec SESector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 4379
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO
Latest News
—
Caricamento notizie per EVO…
stock quote shares EVO – Evotec SE Stock Price stock today
news today EVO – Evotec SE stock forecast ,stock prediction 2023 2024 2025
marketwatch EVO – Evotec SE yahoo finance google finance
stock history EVO – Evotec SE invest stock market
stock prices EVO premarket after hours
ticker EVO fair value insiders trading